Pharmaceutical Commerce: Time to ax copay accumulators?
During our transition, where to find information about:
- Our merged organization: uniting.patientadvocate.org
- Financial assistance: totalassist.org
- Additional direct patient services and resources: patientadvocate.org
- Education: panfoundation.org and education.patientadvocate.org
- Clinical trials education: clinicaltrials.panfoundation.org
- Advocacy: npaf.org
- Research: patientinsightinstitute.org
For patients who are enrolled in private health insurance plans with copay accumulator programs, the value of third-party contributions—such as the value of manufacturer coupons or grants from charitable patient assistance foundations—don’t count toward patients’ deductibles or annual out-of-pocket limits.
In this column for Pharmaceutical Commerce, PAN’s President and CEO, Kevin L. Hagan, and Chief Advocacy and Engagement Officer, Amy Niles, outline how copay accumulator programs are harmful to patients and why they should be banned.